Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL8853445 | 0.98 | CA1 (0.50) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL377275 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL142984 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL3747279 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL4607698 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL23611029 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL161673 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL20593979 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL21638309 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL5604919 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605428-B2 | Kinase NEK10 and its use in treating and diagnosing bronchiectasis and other respiratory disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-11883473-B2 | Treatment of dyslexia using botulinum toxin | PENLAND FOUNDATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230057418-A1 | The Kinase NEK10 and Its Use in Treating and Diagnosing Bronchiectasis and Other Respiratory Disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-23 | — | — | US | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2021231660-A1 | TREATMENT OF DYSLEXIA USING BOTULINUM TOXIN | PENLAND FOUNDATION (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021146704-A1 | THE KINASE NEK10 AND ITS USE IN TREATING AND DIAGNOSING BRONCHIECTASIS AND OTHER RESPIRATORY DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210196803-A1 | TREATMENT OF DYSLEXIA USING BOTULINUM TOXIN | PENLAND FOUNDATION | 2021-07-01 | — | — | US | disclosed |
| US-10967052-B1 | Treatment of dyslexia using botulinum toxin | PENLAND FOUNDATION (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018217766-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-2729023-B1 | MEAT TREATMENT AND PRESERVATION METHOD | RED MEAT AS (NO) | 2015-09-09 | — | — | EP | disclosed |
| US-20140227408-A1 | MEAT TREATMENT AND PRESERVATION METHOD | RED MEAT AS (NO) | 2014-08-14 | — | — | US | disclosed |
| EP-2729023-A1 | MEAT TREATMENT AND PRESERVATION METHOD | Red Meat AS (NO) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013005035-A1 | MEAT TREATMENT AND PRESERVATION METHOD | BERGEN TEKNOLOGIOVERFØRING AS (NO) | 2013-01-10 | — | — | WO | disclosed |
| US-20030194719-A1 | Tpst-assay for diagnosis of autism and related disorders | SHS INTERNATIONAL LTD. (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1272852-A1 | TPST-ASSAY FOR DIAGNOSIS OF AUTISM AND RELATED DISORDERS | SHS International Ltd. (GB) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077681-A1 | TPST-ASSAY FOR DIAGNOSIS OF AUTISM AND RELATED DISORDERS | SHS INTERNATIONAL LTD. (GB) | 2001-10-18 | — | — | WO | disclosed |
| US-5602150-A | TREATMENT OF SCHIZOPHRENIA WITH REDUCED SIDE EFFECTS | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | CA1 2398/4885BBOX1 4011/4885GRM8 179/4885 |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | CA1 2398/4885BBOX1 4011/4885GRM8 179/4885 |
| US-12605428-B2 | Kinase NEK10 and its use in treating and diagnosing bronchiectasis and other respiratory disorders | NEK10, NEK11, NEK1 | CA1 4496/4885BBOX1 4314/4885GRM8 4814/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | CA1 2398/4885BBOX1 4011/4885GRM8 179/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | CA1 2398/4885BBOX1 4011/4885GRM8 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.